Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says

Advisory committee strongly favored approval of postpartum depression therapy, but many members suggest it should be administered in a facility with trained medical staff to avoid potential safety concerns.

FDA Advisory Committee Feature image

SAGE Therapeutics Inc.'s brexanolone could become a game-changing treatment for postpartum depression, but only if it is administered in a highly-controlled setting, US FDA advisory committee members said.

Members of the joint Psychopharmacologic Drugs and Drug Safety and Risk Management advisory committees gave an overwhelmingly positive recommendation of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers